Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
1Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
Hoth Therapeutics, Inc. (HOTH) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
1Distinct source URLs
10High confidence
0.890Average confidence
2026-07-01Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Hoth Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CHELEXA-BIOSCIENCES-INC
CHELEXA-BIOSCIENCES-INC
90%
During the three months ended March 31, 2026 and 2025, the Company recognized expenses of $ 0 and $ 625 , respectively, for license fees associated with the Assignment and Assumption Agreement by and…
MED30-LLC
MED30-LLC
90%
On January 13, 2025, the Company entered into a Patent Application Acquisition Agreement with Med30, LLC (the “Seller”), whereby the Seller sold, conveyed, assigned and transferred to the Company all…
NORTH-CAROLINA-STATE-UNIVERSITY
NORTH-CAROLINA-STATE-UNIVERSITY
90%
During the three months ended March 31, 2026 and 2025, the Company recorded expenses of $ 0 and $ 937 , respectively, for license fees associated with the license agreement by and between the Company…
THE-GEORGE-WASHINGTON-UNIVERSITY
THE-GEORGE-WASHINGTON-UNIVERSITY
90%
During the three months ended March 31, 2026 and 2025, the Company recorded expenses of $ 0 and $ 1,250 , respectively, related to license fees pursuant to the patent license agreement with The Georg…
UNIVERSITY-OF-CINCINNATI
UNIVERSITY-OF-CINCINNATI
90%
During the three months ended March 31, 2026 and 2025, the Company recognized expenses of $ 0 and $ 625 , respectively, for license fees associated with the Assignment and Assumption Agreement by and…
Hoth Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
ZYL-THERAPEUTICS
ZYL-THERAPEUTICS
80%
In connection with the Company's March 2020 underwritten public offering of shares of its common stock, on May 4, 2020, the Company purchased 120,000 shares of Zylö Therapeutics
Hoth Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
HOTH-DEBT-10049
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
HOTH-DEBT-10048
Warrants outstanding: 300000
90%
xbrl warrant detail from xbrl 2025-12-31.
HOTH-DEBT
Debt stack $5,678
90%
Market cache reports total debt of $5,678.
Hoth Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Hoth Therapeutics, Inc..
Hoth Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
HOTH-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC
Geode Capital Management, LLC
90%
13F overlay lists Geode Capital Management, LLC as top holder; 10 tracked holders.
Hoth Therapeutics, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
